...
首页> 外文期刊>International labmate >Custom CAR-T Constructs Service Announced
【24h】

Custom CAR-T Constructs Service Announced

机译:定制Car-T构建服务宣布

获取原文
获取原文并翻译 | 示例
           

摘要

Amsbio announces a Custom Chimeric Antigen Receptor T cell (CAR-T) service designed to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various haematological malignancies. CAR-T cell therapy is a ground-breaking immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognises and eliminates specific cancer cells, independent of major histocompatible complex molecules. The CAR-T cell therapies have been widely used in the treatment of haematological malignancies, including acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, lymphoma, and multiple myeloma.
机译:Amsbio宣布,拟嵌合抗原受体T细胞(CAR-T)服务,旨在利用各种血液无法解决的Car-T细胞实现的令人惊讶的临床突破。 Car-T细胞疗法是一个接地免疫疗法,其中T淋巴细胞与称为嵌合抗原受体(汽车)的合成受体设计。 Car-T细胞是效应T细胞,其识别和消除特异性癌细胞,与主要的组织相容性复合物分子无关。 Car-T细胞疗法已被广泛用于治疗血液恶性肿瘤,包括急性淋巴细胞白血病,慢性淋巴细胞白血病,淋巴瘤和多发性骨髓瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号